Long-term safety of biologics in dermatology

Dermatologic Therapy

Volumn 22, Issue 1, 2009, Pages 2-21

  Lima, Xinaida T ^b   Seidler, Elizabeth M ^b   Lima, Hermênio C ^b   Kimball, Alexandra B ^a,b  

^a Harvard Medical School ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biologics; Dermatology; Long term; Safety

Indexed keywords

ADALIMUMAB; ADRENALIN; ALEFACEPT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; PLACEBO; RITUXIMAB; STEROID; TETANUS TOXOID; TOPICAL AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ABSCESS; ADJUVANT THERAPY; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; APPENDICITIS; ARTHRALGIA; ARTHRITIS; ASEPTIC MENINGITIS; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BRONCHOSPASM; CANCER RISK; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHILL; CHOLELITHIASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEMYELINATING DISEASE; DERMATITIS; DERMATOLOGY; DERMATOMYOSITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA INFECTIOSUM; ERYTHEMA MULTIFORME; ERYTHRODERMA; FATTY LIVER; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL HEMORRHAGE; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HOARSENESS; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RISK; INFLAMMATION; INJECTION SITE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; JUVENILE RHEUMATOID ARTHRITIS; KAPOSI SARCOMA; KIDNEY FAILURE; LEISHMANIASIS; LEUKOPENIA; LICHENOID ERUPTION; LISTERIOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LOW GRADE FEVE; LUNG CARCINOMA; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOMA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; MIGRAINE; MULTIPLE SCLEROSIS; MYALGIA; MYCOSIS; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NOCARDIOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOMYELITIS; PANCYTOPENIA; PAPULAR RASH; PARADOXICAL DRUG REACTION; PARANEOPLASTIC PEMPHIGUS; PATIENT SELECTION; PETECHIA; PHOTOSENSITIVITY; PHOTOTHERAPY; PNEUMONIA; PROSTATE CARCINOMA; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RASH; REBOUND; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RISK FACTOR; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN CANCER; SKIN CARCINOMA; SKIN REDNESS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; TUBULAR DYSFUNCTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VACCINATION; VESICULAR RASH; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING;

EID: 60649100733     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.01212.x     Document Type: Review

References (178)

1. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 : 286 : 954 959.
2. Black LE, Green JD, Rener J, et al. Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies? Hum Exp Toxicol 2000 : 19 : 205 207.
3. Lebwohl M. Psoriasis. Lancet 2003 : 361 : 1197 1204.
4. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 : 58 : 1031 1042.
5. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007 : 143 : 1175 1179.
6. Williams DO, Sharaf BL. Intracoronary radiation: it keeps on glowing. Circulation 2000 : 101 : 350 351.
7. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 : 345 : 248 255.
8. FDA. Alefacept, Amevive, Biogen, Inc. - package insert. Available at: http://www.fda.gov/CDER/foi/label/2003/alefbio013003LB.htm. Accessed October 22, 2008.
9. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 : 58 : 826 850.
10. Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther 2007 : 20 : 270 276.
11. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005 : 27 : 1912 1921.
12. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008 : 159 : 274 285.
13. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 : 349 : 2004 2013.
14. FDA. Raptiva PI. Available at: http://www.fda.gov/medWatch/SAFETY/2005/ Raptiva-PI.pdf. Accessed October 24, 2008.
15. FDA. Raptiva-prescribing. Available at: http://www.gene.com/gene/ products/information/pdf/raptiva-prescribing.pdf. Accessed October 24, 2008.
16. Costanzo A, Peris K, Talamonti M, et al. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007 : 156 (Suppl. 2 17 23.
17. Siegfried EC. Long-term follow-up of a child treated with efalizumab for atopic dermatitis. Arch Dermatol 2007 : 143 : 1077 1078.
18. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000 : 42 : 428 435.
19. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008 : 158 : 1107 1116.
20. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006 : 213 : 204 214.
21. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 2007 : 156 (Suppl. 2 1 6.
22. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 : 54 : S171 S181.
23. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006 : 5 : 197 209.
24. Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol 2008 : 58 : 1053 1055.
25. Ferrandiz C, Carrascosa JM. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. Br J Dermatol 2007 : 156 (Suppl. 2 24 29.
26. Hostetler SG, Zirwas M, Bechtel MA. Efalizumab-associated thrombocytopenia. J Am Acad Dermatol 2007 : 57 : 707 710.
27. Fargnoli MC, Tabilio A, Coletti G, Peris K. Efalizumab-induced immune thrombocytopenia during retreatment. J Am Acad Dermatol 2008 : 58 : S125 S127.
28. Tom WL, Miller MD, Hurley MY, et al. Efalizumab-induced autoimmune pancytopenia. Br J Dermatol 2006 : 155 : 1045 1047.
29. Thachil J, Martlew V. Thrombotic thrombocytopenic purpura with the use of efalizumab for psoriasis. Br J Dermatol 2008 : 158 : 1138 1139.
30. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007 : 11 : 57 66.
31. Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008 : 58 : 1796 1802.
32. Myers WA, Najarian D, Gottlieb AB. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab. J Dermatolog Treat 2006 : 17 : 353 354.
33. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003 : 3 : 148 155.
34. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999 : 116 : 22 28.
35. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006 : 113 : 860 864 e2.
36. Vultaggio A, Matucci A, Parronchi P, et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008 : 21 : 367 374.
37. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003 : 48 : 68 75.
38. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001 : 28 : 47 49.
39. FDA. Infliximab label. Available at: http://www.fda.gov/cder/foi/label/ 2007/103772s5189lbl.pdf. Accessed October 24, 2008.
40. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006 : 4 : 1255 1258.
41. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008 : 14 : 3085 3087.
42. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005 : 11 : 442 446.
43. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008 : 28 : 221 227.
44. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006 : 35 : 857 866.
45. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005 : 52 : 1986 1992.
46. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with infliximab. N Engl J Med 2002 : 346 : 623 626.
47. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008 : 83 : 181 194.
48. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol 2007 : 26 : 2173 2175.
49. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008 : 27 : 541 542.
50. Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006 : 155 : 160 169.
51. Reich K, Griffiths C, Barker J, et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008 : 217 : 268 275.
52. Fuchs I, Avnon L, Freud T, Abu-Shakra M. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clin Rheumatol 2008 : 28 : 167 172.
53. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 : 126 : 19 31.
54. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008 : 38 : 208 217.
55. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006 : 21 : 1366 1371.
56. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001 : 358 : 1042 1045.
57. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006 : 126 : 2194 2201.
58. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 : 295 : 2275 2285.
59. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004 : 50 : 1740 1751.
60. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005 : 52 : 2513 2518.
61. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007 : 46 : 645 660.
62. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004 : 64 : 1767 1777.
63. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNF-alpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006 : 26 : 209 214.
64. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 : 86 : 242 251.
65. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006 : 30 : 41 44.
66. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002 : 100 : 474 482.
67. Han C, Rahman MU, Doyle MK, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007 : 34 : 2177 2182.
68. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005 : 25 : 406 410.
69. Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures - a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum 2008. [Epub ahead of print].
70. Domenech E, Manosa M, Masnou H, et al. Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 2005 : 100 : 496.
71. Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005 : 14 : 780 784.
72. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G. The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. Congest Heart Fail 2002 : 8 : 275 279.
73. Gupta S, Tripathi CD. Current status of TNF blocking therapy in heart failure. Indian J Med Sci 2005 : 59 : 363 366.
74. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002 : 65 : 33 38.
75. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008 : 58 : 667 677.
76. Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008 : 37 : 281 292.
77. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 2007 : 4 : 378 385.
78. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008 : 67 : 1145 1152.
79. Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006 : 31 : 460 461.
80. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 : 56 : 31 e1 15.
81. Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008 : 158 : 138 140.
82. Serwin AB, Sokolowska M, Dylejko E, Chodynicka B. Tumour necrosis factor (TNF-α) alpha converting enzyme and soluble TNF-α receptor type 1 in psoriasis patients in relation to the chronic alcohol consumption. J Eur Acad Dermatol Venereol 2008 : 22 : 712 717.
83. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008 : 58 : 94 105.
84. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002 : 138 : 657 663.
85. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008 : 60 : 8 16.
86. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007 : 8 : 143 155.
87. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008 : 58 : 1496 1504.
88. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008 : 358 : 241 251.
89. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008 : 159 : 1177 1185.
90. Davis JC Jr., van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008 : 67 : 346 352.
91. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 : 143 : 719 726.
92. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007 : 156 : 138 142.
93. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006 : 65 : 1578 1584.
94. FDA. Etanercept (Enbrel) package insert. Available at: http://www.fda.gov/cder/foi/label/2003/etanimm060503LB.pdf. Accessed October 23 2008.
95. Gordon KB, Gottlieb AB, Giannini EH, et al. Clinical trial safety data of events of interest in patients receiving etanercept (Enbrel) across approved indications. Abstract P2610, American Academy of Dermatology 66th Annual Meeting 2008, San Antonio, TX.
96. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 : 38 : 1261 1265.
97. Label EP. Etanercept product label. Available at: http://www.fda.gov/ cder/foi/label/2008/103795s5359lbl.pdf. Accessed October 22, 2008.
98. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002 : 46 : 2565 2570.
99. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003 : 14 : 229 232.
100. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004 : 51 : 580 584.
101. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006 : 20 : 757 790.
102. Gottlieb AB, Gordon KB, Giannini EH, et al. Malignancies from patients receiving etanercept across approved indications. Abstract FRI0113, Annual European Congress of Rheumatology 2008, Paris, France.
103. Yiannias JA, Goldberg LH, Carter-Campbell S, Reddick M, Chamberlain RM. The ratio of basal cell carcinoma to squamous cell carcinoma in Houston, Texas. J Dermatol Surg Oncol 1988 : 14 : 886 889.
104. Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002 : 146 : 334 335.
105. Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007 : 3 : 245 258.
106. Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004 : 22 : S141 S147.
107. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 : 138 : 807 811.
108. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 : 44 : 2862 2869.
109. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006 : 5 : 924 931.
110. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 : 36 : 159 167.
111. Lima HC. Fatos e mitos sobre imunomoduladores. An Bras Dermatol 2007 : 82 : 207 221.
112. FDA. Humira label. Available at: http://www.fda.gov/cder/foi/label/2008/ 125057s114lbl.pdf. Accessed October 24, 2008.
113. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003 : 21 : 3365 3369.
114. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005 : 4 : 637 641.
115. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 2004 : 17 : 427 431.
116. Doraiswamy VA. Nocardia infection with adalimumab in rheumatoid arthritis. J Rheumatol 2008 : 35 : 542 543.
117. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002 : 46 : 2287 2293.
118. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004 : 50 : 1690 1692.
119. Borras-Blasco J, Gracia-Perez A, Nunez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008 : 33 : 321 325.
120. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007 : 26 : 787 778.
121. Atzeni F, Sarzi-Puttini P, Dell' Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006 : 8 : R3.
122. Baidoo L, Lichtenstein GR. What next after infliximab? Am J Gastroenterol 2005 : 100 : 80 83.
123. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007 : 27 : 269 274.
124. Theodoridou A, Kartsios C, Yiannaki E, Markala D, Settas L. Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy. Rheumatol Int 2006 : 27 : 201 202.
125. Salar A, Bessa X, Muniz E, Monfort D, Besses C, Andreu M. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Gut 2007 : 56 : 1169 1170.
126. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006 : 65 : 889 894.
127. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007 : 27 : 369 373.
128. Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton Neurosci 2008 : 143 : 58 67.
129. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci 2006 : 244 : 133 136.
130. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006 : 54 : 1429 1434.
131. Avalos P, Camacho FM. Manejo practico de adalimumab. Actas Dermosifiliogr 2008 : 99 (Suppl. 3 25 27.
132. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003 : 30 : 3 8.
133. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005 : 31 : 456 473.
134. Roche. Roche H-165-PI-en, pp package insert. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Mabthera/H-165-PI-en.pdf. Accessed October 23, 2008.
135. FDA. Genentech package insert. Available at: http://www.fda.gov/medwAtch/ safety/2008/Rituxan-PI.pdf. Accessed October 23, 2008.
136. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008 : 2008 : 1 6.
137. Giulino LB, Bussel JB, Neufeld EJ. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 2007 : 150 : 338 344, 44 e1.
138. Allen KJ, Wolverton SE. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports. J Drugs Dermatol 2007 : 6 : 883 889.
139. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005 : 52 : 601 607.
140. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007 : 56 : 148 153.
141. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007 : 56 : 3107 3111.
142. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007 : 143 : 763 767.
143. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007 : 40 : 273 277.
144. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006 : 108 : 756 762.
145. FDA. Grifols - Flebo ASD ad 07. Available at: http://www.grifolsusa.com/ pdfs/pi/Flebo-ASD%20ad-07.pdf. Accessed October 24, 2008.
146. FDA. Baxter - igivbax042705LB. Available at: http://www.fda.gov/Cber/ label/igivbax042705LB.pdf. Accessed October 24, 2008.
147. FDA. Talecris - gamunexlb. Available at: http://www.fda.gov/CbER/label/ gamunexlb.pdf. Accessed October 24, 2008.
148. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs 2002 : 3 : 713 719.
149. MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006 : 19 : 169 189.
150. Perricone R, De Carolis C, Kroegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford) 2008 : 47 : 646 651.
151. Whitington PF, Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin. Pediatrics 2008 : 121 : e1615 e1621.
152. Williams L, Chang PY, Park E, Gorson KC, Bayer-Zwirello L. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol 2007 : 109 : 561 563.
153. Clark AL. Clinical uses of intravenous immunoglobulin in pregnancy. Clin Obstet Gynecol 1999 : 42 : 368 380.
154. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000 : 84 : 345 352.
155. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003 : 112 : 1430 1436.
156. Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician 2006 : 74 : 1141 1148.
157. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 : 117 : S525 S553.
158. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006 : 6 : 535 542.
159. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004 : 102 : 177 193.
160. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001 : 41 : 264 268.
161. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006 : 142 : 213 217.
162. Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006 : 155 : 714 721.
163. Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005 : 27 : 145 147.
164. Yin F, Nesbitt JA, Tobian AA, Holt PA, Mikdashi J. Hemolytic anemia following intravenous immunoglobulin administration. Am J Hematol 2008 : 83 : 825.
165. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003 : 60 : 1822 1824.
166. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 : 139 : 1051 1059.
167. Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007 : 41 : 1604 1610.
168. Fernandez AP, Kerdel FA. The use of i.v. IG therapy in dermatology. Dermatol Ther 2007 : 20 : 288 305.
169. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007 : 56 : e55 e79.
170. Guhl G, Diaz-Ley B, Fernandez-Herrera J. Uso de farmacos biologicos en dermatosis fuera de la indicacion aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab. Actas Dermosifiliogr 2008 : 99 : 5 33.
171. de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 : 45 : 3 14.
172. Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008 : 66 : 618 625.
173. Insert Gp. Genentech package insert. Available at: http://www.fda.gov/ medwAtch/safety/2008/Rituxan-PI.pdf. Accessed October 23, 2008.
174. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007 : 20 : 277 287.
175. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008 : 121 : 122 128.
176. Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2). J Am Acad Dermatol 2007 : 56 : e1 e54.
177. Pham T, Fautrel B, Gottenberg JE, et al. Rituximab (Mab Thera) therapy and safety management. Cliniacl tool guide. Joint Bone Spine 2008 : 75 : S1 99.
178. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 : 55 : 1 48.